Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
Most patients with renal medullary carcinoma (RMC) have advanced disease at presentation and rarely respond to radiation or chemotherapy. We describe two adolescents with metastatic disease who had significant responses to cisplatin or carboplatin in combination with gemcitabine and paclitaxel.
Strouse
John J
JJ
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA. Jstrous1@jhmi.edu
Spevak
Melissa
M
Mack
A Kyle
AK
Arceci
Robert J
RJ
Small
Donald
D
Loeb
David M
DM
D000293:Adolescent; D001741:Black or African American; D000755:Anemia, Sickle Cell / Q000150:complications; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007679:Kidney Medulla; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine